|
|
Delaware
|
|
001-36399
|
|
42-1560076
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
of incorporation)
|
|
|
|
|
1900 Powell Street, Suite 750
Emeryville, CA
|
|
94,608
|
(Address of principal executive offices)
|
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Executive Officer
|
|
Title
|
|
2017
Salary
|
|
2016 Bonus
|
Gregory T. Went, Ph.D.
|
|
President and Chief Executive Officer
|
|
$517,500
|
|
$250,000
|
William J. Dawson
|
|
Chief Financial Officer
|
|
$358,955
|
|
$104,955
|
Executive Officer
|
|
Title
|
|
Stock Options
|
|
RSUs
|
Gregory T. Went, Ph.D.
|
|
President and Chief Executive Officer
|
|
138,750
|
|
23,125
|
William J. Dawson
|
|
Chief Financial Officer
|
|
45,000
|
|
7,500
|
|
|
Adamas Pharmaceuticals, Inc.
|
|
|
|
|
|
Dated:
|
February 27, 2017
|
By:
|
/s/ Jennifer Rhodes
|
|
|
|
Jennifer Rhodes
|
|
|
|
Chief Business Officer, General Counsel, & Compliance Officer
|